JP2022538237A5 - - Google Patents

Info

Publication number
JP2022538237A5
JP2022538237A5 JP2021576635A JP2021576635A JP2022538237A5 JP 2022538237 A5 JP2022538237 A5 JP 2022538237A5 JP 2021576635 A JP2021576635 A JP 2021576635A JP 2021576635 A JP2021576635 A JP 2021576635A JP 2022538237 A5 JP2022538237 A5 JP 2022538237A5
Authority
JP
Japan
Prior art keywords
approximately
subject
pharmaceutical composition
dose
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021576635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/055872 external-priority patent/WO2020261093A1/en
Publication of JP2022538237A publication Critical patent/JP2022538237A/ja
Publication of JP2022538237A5 publication Critical patent/JP2022538237A5/ja
Priority to JP2025087586A priority Critical patent/JP2025138634A/ja
Withdrawn legal-status Critical Current

Links

JP2021576635A 2019-06-24 2020-06-22 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 Withdrawn JP2022538237A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087586A JP2025138634A (ja) 2019-06-24 2025-05-27 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962865381P 2019-06-24 2019-06-24
US62/865,381 2019-06-24
US201962940589P 2019-11-26 2019-11-26
US62/940,589 2019-11-26
US202062967401P 2020-01-29 2020-01-29
US62/967,401 2020-01-29
US202063034106P 2020-06-03 2020-06-03
US63/034,106 2020-06-03
PCT/IB2020/055872 WO2020261093A1 (en) 2019-06-24 2020-06-22 Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087586A Division JP2025138634A (ja) 2019-06-24 2025-05-27 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療

Publications (2)

Publication Number Publication Date
JP2022538237A JP2022538237A (ja) 2022-09-01
JP2022538237A5 true JP2022538237A5 (cg-RX-API-DMAC7.html) 2023-06-27

Family

ID=71738213

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576635A Withdrawn JP2022538237A (ja) 2019-06-24 2020-06-22 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
JP2025087586A Pending JP2025138634A (ja) 2019-06-24 2025-05-27 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087586A Pending JP2025138634A (ja) 2019-06-24 2025-05-27 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療

Country Status (10)

Country Link
US (1) US20220332821A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986569A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022538237A (cg-RX-API-DMAC7.html)
KR (1) KR20220024729A (cg-RX-API-DMAC7.html)
CN (2) CN114286828A (cg-RX-API-DMAC7.html)
AU (1) AU2020307471A1 (cg-RX-API-DMAC7.html)
CA (1) CA3144324A1 (cg-RX-API-DMAC7.html)
IL (1) IL289187A (cg-RX-API-DMAC7.html)
TW (1) TW202115114A (cg-RX-API-DMAC7.html)
WO (1) WO2020261093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
HUE068401T2 (hu) 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
JP2023524854A (ja) * 2020-05-13 2023-06-13 ファイザー・インク がんを処置するための方法、治療、および使用
KR20230069181A (ko) * 2020-09-14 2023-05-18 화이자 인코포레이티드 암 치료를 위한 방법, 요법 및 용도
JP2024504454A (ja) * 2021-01-29 2024-01-31 上▲海▼翰森生物医▲薬▼科技有限公司 抗体-薬物コンジュゲート及びその医学的使用
CN115521381B (zh) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
TW202325743A (zh) * 2021-07-14 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合cd38、bcma和cd3的抗原結合分子及其醫藥用途
CN113908395B (zh) * 2021-10-13 2024-05-17 科悦医疗(苏州)有限公司 一种促醒仪
EP4426437A4 (en) * 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
KR20260057078A (ko) * 2023-08-18 2026-04-27 브리스톨-마이어스 스큅 컴퍼니 Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
BRPI0413533A (pt) 2003-09-09 2006-10-10 Hoffmann La Roche derivados de malonamida que bloqueiam a atividade de gama-secretase
EP1680406A1 (en) 2003-10-29 2006-07-19 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
EP1702626B1 (en) 2003-12-30 2011-11-30 Kowa Company, Ltd. Screening method for gamma-secretase inhibitors
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
CA2641013A1 (en) 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
EP2011513B1 (en) 2006-04-25 2016-10-19 The University of Tokyo Therapeutic agents for alzheimer's disease and cancer
US20110257163A1 (en) 2007-08-07 2011-10-20 Schering Corporation Gamma secretase modulators
KR101136260B1 (ko) 2007-08-14 2012-04-19 일라이 릴리 앤드 캄파니 감마-세크레타제 억제제로서의 아제핀 유도체
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯二氮呯酮化合物
US9096582B2 (en) 2011-10-31 2015-08-04 Merck Sharp & Dohme Corp Gamma secretase modulators
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
EP2925313A4 (en) 2012-11-29 2016-05-11 Merck Sharp & Dohme SPIROCYCLIC SULPHONES AS GAMMA SECRETASE INHIBITORS
UY36401A (es) * 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
JP6696982B2 (ja) * 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
HK1245171A1 (zh) * 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
EP3324965A4 (en) 2015-07-24 2019-07-03 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
CN109310755A (zh) * 2016-02-02 2019-02-05 卡德门企业有限公司 Pd-l1和kdr的双特异性结合蛋白
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
PE20210320A1 (es) * 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas

Similar Documents

Publication Publication Date Title
JP7160533B2 (ja) 多発性骨髄腫(mm)の処置
JP2021113190A5 (cg-RX-API-DMAC7.html)
JP2024540275A5 (cg-RX-API-DMAC7.html)
JP2023520771A5 (cg-RX-API-DMAC7.html)
JP2023551877A5 (cg-RX-API-DMAC7.html)
CN118201613A (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
JP2022547577A5 (cg-RX-API-DMAC7.html)
JP2003505432A (ja) 抗ep−cam抗体と化学療法剤との組合せ
JP2024543885A5 (cg-RX-API-DMAC7.html)
TW202508631A (zh) 使用抗cd40l抗體治療多發性硬化症
JP2022514561A5 (cg-RX-API-DMAC7.html)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2024535431A5 (cg-RX-API-DMAC7.html)
JP2023546504A5 (cg-RX-API-DMAC7.html)
WO2025122791A1 (en) Use of anti-cd38 antibody in the treatment of new diagnosed multiple myeloma
WO2025007946A1 (zh) 治疗前列腺癌的方法
CN112773802B (zh) 一种化合物用于预防或治疗移植物抗宿主病的用途
JP2024524552A (ja) 多発性骨髄腫の治療に使用するためのメルフルフェン
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
JP2023534765A5 (cg-RX-API-DMAC7.html)
JP2024524552A5 (cg-RX-API-DMAC7.html)
US12263245B2 (en) Immunomodulating treatments of body cavities
JPS5821624A (ja) 慢性関節リウマチの治療剤
JP2025505381A5 (cg-RX-API-DMAC7.html)
HK40124218A (en) Composition and method for prolong survival of transplant and recipient